FIL Ltd lifted its holdings in Celgene Corporation (NASDAQ:CELG) by 76.7% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 715,260 shares of the biopharmaceutical company’s stock after buying an additional 310,452 shares during the quarter. FIL Ltd owned approximately 0.09% of Celgene worth $92,891,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. BlackRock Inc. lifted its position in Celgene by 5.7% in the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after purchasing an additional 3,084,227 shares during the last quarter. Oaktop Capital Management II L.P. bought a new stake in Celgene in the 2nd quarter valued at about $271,605,000. Vanguard Group Inc. lifted its position in Celgene by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after purchasing an additional 1,610,056 shares during the last quarter. Harbour Capital Advisors LLC lifted its position in Celgene by 12,913.6% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,587,271 shares of the biopharmaceutical company’s stock valued at $12,222,000 after purchasing an additional 1,575,074 shares during the last quarter. Finally, Investec Asset Management LTD bought a new stake in Celgene in the 1st quarter valued at about $194,490,000. Institutional investors own 79.48% of the company’s stock.
Several analysts recently weighed in on CELG shares. Morgan Stanley downgraded shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective on the stock. in a research report on Thursday, October 5th. BTIG Research reiterated a “hold” rating on shares of Celgene in a research report on Sunday, October 22nd. Cantor Fitzgerald reiterated a “hold” rating and issued a $112.00 price objective on shares of Celgene in a research report on Monday, October 30th. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target on the stock in a research report on Monday, October 23rd. Finally, Citigroup Inc. downgraded shares of Celgene from a “buy” rating to a “neutral” rating in a research report on Friday, October 20th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $139.57.
Celgene Corporation (NASDAQ:CELG) opened at $104.50 on Monday. The stock has a market cap of $82,274.63, a P/E ratio of 16.33, a PEG ratio of 0.81 and a beta of 1.79. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. Celgene Corporation has a 52 week low of $94.55 and a 52 week high of $147.17.
Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The business’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.58 EPS. research analysts expect that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.
In other news, Director Gilla Kaplan sold 9,250 shares of Celgene stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the transaction, the director now directly owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The disclosure for this sale can be found here. Over the last three months, insiders sold 20,227 shares of company stock worth $2,843,956. 0.95% of the stock is currently owned by insiders.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.